Columbus OH 多发性硬化症临床试验
7项针对 多发性硬化症的研究正在 Columbus及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
招募中2 期
- Local Institution - Site 104, Columbus
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
招募中1 期
- Ohio State University Comprehensive Cancer Center, Columbus
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
招募中观察性研究
- TG Therapeutics Investigational Trial Site, Columbus
- TG Therapeutics Investigational Trial Site, Columbus
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
招募中3 期
- The Ohio State University- Site Number : 8400009, Columbus
- The Boster Center for Multiple Sclerosis- Site Number : 8400006, Columbus
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
招募中2 期
- The Ohio State University, Department of Psychiatry, Columbus
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
招募中2 期
- Riverside Methodist Hospital, Columbus
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
招募中1 期
- TG Therapeutics Investigational Trial Site, Columbus
其他城市的 多发性硬化症试验
- New York City, NY17 项研究
- Chicago, IL15 项研究
- Boston, MA14 项研究
- Washington, DC13 项研究
- Cleveland, OH9 项研究
- Kansas City, KS8 项研究
- San Francisco, CA8 项研究
- Birmingham, AL8 项研究
- St. Louis, MO8 项研究
- Seattle, WA7 项研究
- Aurora, CO7 项研究
- Baltimore, MD7 项研究
Columbus的其他研究
- 非小细胞肺癌54 项研究
- 卵巢癌40 项研究
- 乳腺癌39 项研究
- 癌症(所有类型)39 项研究
- 肺癌36 项研究
- 急性髓系白血病34 项研究
- 慢性淋巴细胞白血病29 项研究
- 子宫内膜癌26 项研究
- 转移性癌症26 项研究
- 多发性骨髓瘤24 项研究
- 前列腺癌24 项研究
- 结直肠癌23 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年9月29日。每项研究自行设定入选标准,由研究团队决定谁能参与。